| Recruiting | Atmospheric Pressure Cold Plasma for Moderate-to-severe Tinea Pedis NCT07056660 | Shenyang Medical College | N/A |
| Not Yet Recruiting | Efficacy of Tropical Sertaconazole Nitrate 2% Vs Clotrimazole 1% for Tinea Pedis NCT06869681 | Jinnah Postgraduate Medical Centre | Phase 4 |
| Recruiting | Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study NCT07245667 | Propedix, Inc. | Phase 2 |
| Unknown | A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tine NCT05493488 | DermBiont, Inc. | Phase 2 |
| Completed | Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis NCT05363449 | Therapeutics, Inc. | Phase 1 |
| Completed | A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis. NCT04883593 | Sun Pharmaceutical Industries, Inc. | EARLY_Phase 1 |
| Completed | Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry F NCT04265521 | Biocool AB | N/A |
| Completed | A Therapeutic Equivalence Study of Ketoconazole Cream 2% NCT04203342 | Douglas Pharmaceuticals America Ltd | Phase 3 |
| Completed | A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis NCT03897257 | Therapeutics, Inc. | Phase 2 |
| Completed | A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis NCT04152226 | DermBiont, Inc. | Phase 2 |
| Unknown | SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFI NCT03999437 | United Laboratories | Phase 2 |
| Completed | Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis NCT03676686 | Natumin Pharma AB | N/A |
| Completed | Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedi NCT03824912 | Encube Ethicals Pvt. Ltd. | Phase 3 |
| Completed | Non-inferiority Trial of Dapaconazole Versus Ketoconazole NCT03320486 | Biolab Sanus Farmaceutica | Phase 3 |
| Completed | Three-Arm Trial of Novel Treatment for Tinea Pedis NCT03135912 | South End Skin Care | Phase 2 |
| Terminated | Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis NCT02842021 | Sol-Gel Technologies, Ltd. | Phase 2 |
| Completed | Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot NCT02871011 | Nitric Solutions Inc. | Phase 2 |
| Completed | SB208 for the Treatment of Tinea Pedis NCT02860052 | Novan, Inc. | Phase 2 |
| Withdrawn | Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Ti NCT02606383 | Biolab Sanus Farmaceutica | Phase 3 |
| Completed | Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis NCT03129321 | Mylan Inc. | Phase 3 |
| Completed | Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cr NCT02767271 | Bausch Health Americas, Inc. | Phase 4 |
| Completed | BE Study of Naftifine HCL NCT02633813 | Genzum Life Sciences | Phase 3 |
| Completed | Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and NCT02394340 | Bausch & Lomb Incorporated | Phase 4 |
| Completed | Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis NCT02824926 | Gilberto De Nucci | Phase 2 |
| Completed | Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis NCT02335255 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tin NCT02132260 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Ti NCT01891305 | Viamet | Phase 2 |
| Completed | Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis NCT01712360 | Merz North America, Inc. | Phase 4 |
| Completed | Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis NCT01580891 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Unknown | Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections NCT01105013 | Laboratório Teuto Brasileiro S/A | Phase 3 |
| Completed | Hygienic Socks With Antifungal Agent-loaded Microcapsules for Patients With Tinea Pedis NCT01524432 | Prof. Yuen Chun-Wah | Phase 1 |
| Completed | Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehic NCT01580878 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pe NCT01519752 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis NCT01433107 | Novartis | Phase 3 |
| Completed | Topical Antifungal Treatment for Tinea Pedis NCT01396811 | Medicis Global Service Corporation | Phase 3 |
| Completed | Topical Antifungal Treatment for Tinea Pedis NCT01396785 | Medicis Global Service Corporation | Phase 3 |
| Completed | Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis NCT01358240 | AmDerma | Phase 3 |
| Completed | Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis NCT01349998 | Tinea Pharmaceuticals | Phase 3 |
| Completed | Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis NCT01353976 | AmDerma | Phase 3 |
| Completed | Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis NCT01290341 | Merz North America, Inc. | Phase 3 |
| Completed | Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis NCT01289015 | Merz North America, Inc. | Phase 3 |
| Completed | Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis NCT01096472 | Almirall, S.A. | Phase 2 |
| Completed | Comparative Safety and Efficacy Study of New Bifonazol Spray vs Terbinafine Solution vs Placebo NCT01013909 | Bayer | Phase 2 |
| Completed | A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis NCT00893880 | Nitric BioTherapeutics, Inc | Phase 2 |
| Unknown | Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot) NCT00848666 | Hillel Yaffe Medical Center | N/A |
| Completed | Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot) NCT00869336 | Tinea Pharmaceuticals | Phase 2 |
| Unknown | Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females NCT00856596 | Jamaica Hospital Medical Center | Phase 3 |
| Completed | Cumulative Irritation Test NCT00781664 | Pfizer | Phase 1 |
| Completed | Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis NCT00750139 | Merz North America, Inc. | Phase 3 |
| Completed | Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis NCT00835510 | Sun Pharmaceutical Industries, Inc. | Phase 1 |
| Completed | A Study of Econazole Foam 1% in Athlete's Foot NCT00768599 | AmDerma | Phase 2 |
| Terminated | An Efficacy Study of a New Formulation of Ketoconazole 2% Cream in Patients With Tinea Pedis, Commonly Known a NCT01110330 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Completed | A Study to Evaluate Efficacy and Safety of Three W0027 Regimens in the Treatment of Moccasin Type Tinea Pedis NCT00509275 | Stiefel, a GSK Company | Phase 1 |
| Completed | Spread of Dermatophytes Among Families NCT00233493 | University Hospitals Cleveland Medical Center | — |
| Completed | Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox NCT00804193 | Padagis LLC | N/A |
| Completed | Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% NCT00802672 | Padagis LLC | Phase 3 |